Analysts Set OptimizeRx Co. (NASDAQ:OPRX) PT at $16.00

Shares of OptimizeRx Co. (NASDAQ:OPRX) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $16.07.

Several analysts recently commented on OPRX shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price target on shares of OptimizeRx in a research note on Wednesday, May 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 target price on shares of OptimizeRx in a report on Monday, April 1st. JMP Securities reissued a “market outperform” rating and set a $16.00 price target on shares of OptimizeRx in a report on Friday, June 21st. Finally, B. Riley started coverage on shares of OptimizeRx in a report on Thursday. They set a “buy” rating and a $18.50 price target for the company.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors have recently modified their holdings of OPRX. Millrace Asset Group Inc. bought a new position in shares of OptimizeRx in the fourth quarter worth about $1,917,000. G2 Investment Partners Management LLC raised its stake in shares of OptimizeRx by 26.0% in the fourth quarter. G2 Investment Partners Management LLC now owns 468,120 shares of the company’s stock worth $6,699,000 after acquiring an additional 96,646 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in shares of OptimizeRx in the first quarter worth about $1,053,000. Rice Hall James & Associates LLC raised its stake in shares of OptimizeRx by 17.3% in the first quarter. Rice Hall James & Associates LLC now owns 401,882 shares of the company’s stock worth $4,883,000 after acquiring an additional 59,141 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of OptimizeRx in the first quarter worth about $542,000. 76.47% of the stock is owned by institutional investors.

OptimizeRx Price Performance

Shares of OPRX opened at $10.70 on Friday. OptimizeRx has a 12-month low of $6.92 and a 12-month high of $16.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 2.88 and a current ratio of 2.88. The stock’s 50-day moving average price is $10.95 and its 200 day moving average price is $12.34.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). OptimizeRx had a negative net margin of 23.10% and a negative return on equity of 6.96%. The firm had revenue of $19.69 million for the quarter, compared to the consensus estimate of $18.66 million. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. On average, analysts predict that OptimizeRx will post -0.46 earnings per share for the current year.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.